先進ドラッグデリバリーの世界市場規模：製品別、用途別、地域別、範囲および予測

先進ドラッグデリバリーの市場規模と予測

先進ドラッグデリバリー市場規模は、2024年に774億9,000万米ドルと評価され、2024年から2031年にかけてCAGR 18.60%で成長し、2031年には3,033億2,000万米ドルに達すると予測されます。先進ドラッグデリバリーは、薬剤の放出速度を調節します。疾患の種類、薬物、望ましい結果はすべて、使用される技術革新に影響を与えます。先進ドラッグデリバリーシステムの目標は、治療量の薬剤を体内の特定部位に可能な限り迅速に送達し、薬剤の目標濃度を達成・維持することです。先進ドラッグデリバリーの世界市場レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、市場抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界の先進ドラッグデリバリー市場の定義

先進ドラッグデリバリーシステムは、薬物分子をより制御された方法で所望の標的に送達するための最適化された方法です。これらの方法は、既存の薬剤の治療効果を高めるために開発されています。先進ドラッグデリバリーシステムの進歩は、所定の速度で薬物を送達すること、また現場での薬物放出と吸収のためにゆっくりと標的を絞って送達することが前提となっています。

特定の部位により選択的に薬物を送達する能力、より容易で正確な、より一般的でない投与、全身薬物レベルのばらつきの減少、部位や作用機序に応じてより一定な吸収、毒性化合物の減少などはすべて、従来のシステムに対する先進ドラッグデリバリーシステムの大きな利点です。

先進ドラッグデリバリーシステムは、標的薬物デリバリー、高分子薬物デリバリー、徐放性薬物デリバリー、インプラント・IUD、プロドラッグに分類されます。ターゲット・ドラッグ・デリバリーとは、従来のドラッグ・デリバリーが持つ特異的な毒性作用を解消し、治療効果に必要な薬物量を減らすために、薬物部分を目的の身体部位に直接供給するプロセスです。プロドラッグとは、薬理学的活性を持たない分子で、生体内で酵素的、化学的、あるいは両者の混合によって活性のある親薬物に変化します。

プロドラッグは、可能性によって発見され、救済措置として使用されていたものから、明確に設計されるようになった。先進ドラッグデリバリーシステムには、経口、非経口、肺、皮下、経皮、およびナノ構造、ナノスフェア、ナノカプセル、ナノ粒子、リポソーム、ノゾーム、デンドリマー、合成ポリマーや脂質をベースとしたキャリアなどのナノサイズの小胞キャリア、その他のドラッグデリバリーシステムなどのキャリアベースのシステムが含まれます。

先進ドラッグデリバリーの世界市場概要

成長を促進する主な要因の一つは、人口全体における慢性疾患の急速な広がりです。慢性疾患は、1年以上持続し、継続的な医療を必要とするか、日常的な活動を制限するか、またはその両方を必要とする問題として広く知られています。さらに、世界の医療費の大幅な増加が、先進ドラッグデリバリー市場を強化しています。

医療費増加の主な原因は、人口の増加、特に老年人口の増加、慢性疾患の増加、医療サービスの利用拡大です。新しい薬剤分子をもたらすための研究開発活動の活発化。薬力学、薬物毒性、免疫原性、生体適合性、薬物動態学的特性、薬剤化合物の有効性を高めるために、さまざまな先進的ドラッグデリバリー・ルートを開発することで、科学技術の進歩が進んでいます。

さらに、先進ドラッグデリバリーシステム開発のための政府からの資金援助や融資、新製品、共同パートナーシップの増加が、予測期間中の市場成長を後押しすると予測されます。薬剤のリコールや薬剤の失敗の大幅な増加は、先進ドラッグデリバリー市場の成長を制限すると予想されます。方法開発における特定の技術的困難、より厳しい規制、先進製品の高価格、低所得国での入手不可能性などが、世界の先進ドラッグデリバリー市場の成長を制限する要因となっています。

ヘルスケア費用の増加は、消費者の健康に対する意識の高まり、政府や企業の取り組みの強化、低開発国や発展途上国における消費者の需要を満たすための非公開会社による政府投資に起因しています。その結果、これらすべての要因が、研究・革新プロセスへの投資や、既存薬だけでなく今後開発される新規分子体の薬効改善と確実な治療のための先進ドラッグデリバリーソリューション開発の機会を提供し、市場の成長を加速させています。

目次

第1章 世界の先進ドラッグデリバリー市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• 検証
• プライマリーインタビュー
• データソース一覧

第4章 先進ドラッグデリバリーの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 先進ドラッグデリバリーの世界市場：製品別

• 概要
• インプラントとIUD
• 徐放性薬物送達
• 標的ドラッグデリバリー
• プロドラッグ
• 高分子ドラッグデリバリー

第6章 先進ドラッグデリバリーの世界市場：用途別

• 概要
• 診断センター
• 外来手術センター/クリニック
• 在宅医療
• 病院
• その他

第7章 先進ドラッグデリバリーの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の先進ドラッグデリバリー市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• GlaxoSmithKline
• Merck & Co
• Antares Pharma
• Allergan
• F. Hoffmann-La Roche
• Novartis
• Sanofi
• 3M
• Johnson & Johnson
• Pfizer

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Advanced Drug Delivery Market Size And Forecast

Advanced Drug Delivery Market size was valued at USD 77.49 Billion in 2024 and is projected to reach USD 303.32 Billion by 2031, growing at a CAGR of 18.60% from 2024 to 2031. Advanced drug delivery regulates the rate at which drugs are released. The type of disease, drug, and preferred outcome all have an impact on the innovation used. An advanced drug delivery system's goal is to deliver a therapeutic amount of medication to a specific site in the body as quickly as possible to achieve and then preserve the target concentration of the drug. The Global Advanced Drug Delivery Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Advanced Drug Delivery Market Definition

Advanced drug delivery systems are optimized methods for delivering the drug molecule to the desired target in a more controlled way. These methods are being developed to enhance the improved therapeutic ratio of existing drugs. The advancement of advanced drug delivery systems is predicated on the delivery of drugs at a predetermined rate, and also slow and targeted delivery for onsite drug release and absorption.

The ability to deliver a drug more selectively to a particular site, easier, more precise, less common dosing, reduced variability in systemic drug levels, absorption that is more constant with the site and mode of action, and reductions in toxic compounds are all major benefits of advanced drug delivery systems over traditional systems.

The Advanced Drug Delivery System is classified as Targeted Drug Delivery, Polymeric Drug Delivery, Sustained Release, Implants & IUDs, and Prodrugs. Targeted drug delivery is a process of providing a drug moiety directly into its intended body area to resolve the specific toxic effect of conventional drug delivery and thus decrease the amount of drug needed for therapeutic efficacy. Prodrugs are molecules with no pharmacological activity that are transformed to the active parent drug in vivo through enzymatic, chemical, or a mixture of the two.

Prodrugs have advanced from being discovered by possibility and used as a salvage effort to just being designed explicitly. The advanced drug delivery system contains oral, parenteral, pulmonary, subcutaneous, transdermal, and carrier-based systems such as nanostructures, Nanospheres, Nanocapsules, nanoparticles, and Nano-sized vesicular carriers including such liposomes, noisome, dendrimers, and synthetic polymer or lipid-based carriers, and other drug delivery systems.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Advanced Drug Delivery Market Overview

One of the major factors driving the growth is the rapid spread of chronic diseases in the overall population. The chronic disease known broadly as a problem that lasts a year or longer and necessarily require ongoing medical care, confine daily activities, or both. Moreover, the substantial increase in global health expenditures has enhanced the Advanced Drug Delivery Market.

The main causes of the increase in medical expenditure are a rise in population, especially geriatrics, an increase in chronic conditions, and enhanced medical service utilization. Growing R&D activities to bring new drug molecules. By developing different advanced drug delivery routes, science and technological advances have been made to develop advanced drug delivery systems to increase the pharmacodynamics, drug toxicity, immunogenicity, biocompatibility, pharmacokinetic properties, and efficacy of drug compounds.

Furthermore, increased government funding and financing, new products, and collaborative partnerships for the development of advanced drug delivery systems are projected to boost market growth over the forecast period. The substantial rise in the number of drugs recalls and drug failures are expected to restrict the growth of the Advanced Drug Delivery Market. Certain technical difficulties in method development, stricter regulations, high pricing for advanced products, and non-availability in low-income countries are among the factors that limit Global Advanced Drug Delivery Market growth.

The increase in healthcare costs has been attributed to the increased consumer awareness of health, enhanced government and corporate initiatives, and government investment by public-private sector companies to fulfill consumer demands in underdeveloped and developing countries. As an outcome, all of these factors provide opportunities for investments in the Research and innovation process and the development of advanced drug delivery solutions for improved drug efficacy and secure therapy for existing drugs as well as upcoming novel molecular entities, which accelerates the market growth.

Global Advanced Drug Delivery Market Segmentation Analysis

The Global Advanced Drug Delivery Market is segmented on the basis of Product, Application, And Geography.

Advanced Drug Delivery Market, By Product

• Polymeric Drug Delivery
• Implants & IUD's
• Sustained Release
• Targeted Drug Delivery
• Prodrugs

Based on Product, The market is segmented into Polymeric Drug Delivery, Implants & IUD's, Sustained Release, Targeted Drug Delivery, and Prodrugs. Targeted Drug Delivery has the highest growing segment of the Global Drug Delivery System Market because of increased drug accessibility, reduced toxicity, effective targeted therapy, and lowered active drug degradation over the forecasted period.

Advanced Drug Delivery Market, By Application

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers/Clinics
• Home Care Settings
• Others

Based on the Application, The market is segmented into Hospitals, Diagnostic Centers, Ambulatory Surgical Centers/Clinics, Home Care Settings, and Others. Hospitals have the fastest-growing segment of the Global Drug Delivery System Market. because of a rise in the number of in-patients and out-patient visits, However, this leading to an increase in chronic illnesses including such neurology, cardiology, and orthopedics, as well as a growth of the market for drug delivery treatment, the highly specialized clinics segment accounting for almost half of the global Advanced Drug Delivery Market.

Advanced Drug Delivery Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Advanced Drug Delivery Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is projected to be the largest growing market throughout the forecasted period. This is attributed to the increase in the integration of advanced as a result of improved drug delivery solutions, and increasing healthcare expenses in the region over the projected period.

Key Players

• The "Global Advanced Drug Delivery Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• GlaxoSmithKline, Merck & Co, Antares Pharma, Allergan, F. Hoffmann-La Roche, Novartis, Sanofi, 3M, Johnson & Johnson, Pfizer, Abbott Laboratories, Bayer.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In February 2019, Sandoz, a Novartis division and world leader in biosimilars, received European Commission authorization in Spain for its adalimumab biosimilar, HYRIMOZ, for subcutaneous injection in a syringe or a prefilled pen.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ADVANCED DRUG DELIVERY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ADVANCED DRUG DELIVERY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Implants & IUD's
• 5.3 Sustained Release
• 5.4 Targeted Drug Delivery
• 5.5 Prodrugs
• 5.6 Polymeric Drug Delivery

6 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Diagnostic Centres
• 6.3 Ambulatory Surgical Centers/Clinics
• 6.4 Home Care Settings
• 6.5 Hospitals
• 6.6 Others

7 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.3 Canada
  • 7.2.4 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL ADVANCED DRUG DELIVERY MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Merck & Co
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Antares Pharma
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Allergan
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 F. Hoffmann-La Roche
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Novartis
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Sanofi
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 3M
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Johnson & Johnson
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Pfizer
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research